Invetech And Biocartis Announce Collaboration Agreement For Production Of Multiplex Biomarker Analysis Platform Evalution™
Invetech, a global leader in instrument development, custom automation, and contract manufacturing, and Biocartis, a diagnostics company focused on improving healthcare outcomes via the practice of personalized medicine, today announced a collaboration agreement to support development and manufacture of Evalution™, Biocartis’ advanced multiplex platform for analysis of a broad range of protein and nucleic acid-based biomarkers.
The Evalution™ platform, designed to support a range of applications in the clinical research and pharmaceutical markets, provides an integrated reaction and detection environment and supports simultaneous analysis of large numbers of analytes per assay. The technology offers real-time visualization of the reaction and data traceability for easy and reliable assay development.
“We first established a collaborative agreement with Biocartis in 2008 when they were a relatively small startup company. Since that time, our team has delivered the full range of our product realization expertise to support their rapid growth and expansion, from project initiation right through to manufacturing. In addition to our instrument development services, we have provided Biocartis with guidance in areas including regulatory, sustaining engineering and instrument service. We look forward to continuing our relationship to help them advance and maximize the potential of the Evalution™ platform in the years ahead,” said David James, senior vice president, diagnostics, of Invetech.
Evalution™ is engineered to reduce hands-on time and development complexity, with the potential to streamline procedures for biomarker verification and validation. Currently, Biocartis has multiple scientific collaborations and partnerships in place for the development of novel content on the Evalution™ platform, targeting development of assays in the fields of oncology, cardiology, neurology, and immunology.
“At every stage in our growth, and our focus on product development and manufacturing, our relationship with Invetech has been marked by a high level of collaboration as well as outstanding responsiveness, ease of communication, and flexibility. We look forward to their contributions to the production and expansion of the Evalution™ platform and our efforts to improve data quality, speed to results, and cost-effectiveness in bioassays around the world,” said Paul Ladestein, managing director, business unit Evalution, Biocartis.
About Invetech
Invetech is your trusted partner in solving complex manufacturing and product development challenges in the global advanced therapies market. For more than three decades, we’ve partnered with leaders in diagnostics, life sciences, and cell therapy to co-create breakthrough solutions that transform ideas into market-ready technologies and therapies. Whether transitioning from early process development to commercial-scale manufacturing or optimizing complex workflows, our team combines scientific insight, engineering excellence and proven technology platforms to deliver tailored solutions. Our proven modules, technology platforms and custom automation solutions integrate seamlessly with your processes, reducing time to market, and supporting scalable, GMP-compliant manufacturing. Together with our clients, we’re advancing healthcare.
To learn more about Invetech Group, visit https://www.invetechgroup.com/
About Biocartis
Biocartis aims to improve quality of life by enabling direct access to personalized medicine to patients worldwide. Its goal is to advance medical treatment through the broad implementation of state-of-the-art diagnostic tests performed close to the clinical decision-making point.
Biocartis’ innovative research and diagnostic systems feature the detection of molecular components, which are indicative for a specific pathological state. The new systems are highly user-friendly, require less hands-on time and minimize the handling of valuable samples. In addition, Biocartis develops assays with major clinical and compelling health economic value. Oncology, neurology, cardiology and immunology are Biocartis’ focus.
Biocartis is a rapidly growing company that currently employs close to 200 people. It has offices in Belgium (close to Brussels) and in Switzerland (Lausanne).
For more information contact:
Emily Ellinger, Marketing &
Communications Manager,
Invetech
emily.ellinger@invetech.com.au
